A biotechnology sponsor developing a novel intratumoral radiosensitizer required support to conduct a complex Phase 1/2 multinational clinical trial evaluating the therapy in patients with locally advanced cervical cancer. The study required rapid activation across India, Thailand, and the United States, each with distinct regulatory frameworks, operational challenges, and patient recruitment environments. ProRelix Research implemented a hybrid decentralized trial model, accelerated regulatory approval strategy, and data-driven site selection process to support efficient global execution. The program achieved strong operational performance, including accelerated enrollment, high patient retention, and significant cost efficiencies, demonstrating how modern clinical trial models can enable faster oncology development.
Therapeutic Area: Oncology
Indication: Locally Advanced Cervical Cancer
Study Phase: Phase 1/2
Regions: India, Thailand & United States
Study Design: Hybrid Decentralized Clinical Trial
Sponsor Type: Mid-size Biotechnology Company
→ First patient enrolled within 3.5 weeks
→ Enrollment completed two months ahead of schedule
→ 94% patient retention rate
→ 98% data accuracy with 100% clean database lock
→ 23% reduction in total trial execution cost
A biotechnology sponsor developing a first-in-class intratumoral radiosensitizer sought to advance its therapy into clinical evaluation for patients with locally advanced cervical cancer. While radiotherapy remains a cornerstone of treatment, its effectiveness is often reduced in hypoxic tumor environments. The sponsor’s investigational therapy was designed to selectively target these hypoxic cells and improve radiotherapy outcomes. To evaluate the therapy’s safety and early efficacy, a Phase 1/2 multinational clinical trial was initiated. However, the program faced several operational challenges:
The sponsor required a CRO partner capable of delivering regulatory expertise, operational scalability, and innovative trial execution strategies across multiple global regions.
ProRelix Research implemented a comprehensive strategy to ensure efficient trial execution while maintaining scientific rigor and regulatory compliance.
The trial incorporated a hybrid decentralized approach designed to improve patient accessibility and reduce participation barriers. Digital infrastructure enabled:
This model expanded patient reach while ensuring consistent data collection and clinical oversight.
An AI-supported feasibility assessment was used to identify oncology centers with strong experience in cervical cancer research and radiotherapy-integrated treatment protocols. This ensured that selected sites possessed both the clinical expertise and recruitment capabilities required for a complex early-phase oncology trial.
To reduce activation timelines, ProRelix Research executed parallel regulatory submissions across India, Thailand, and the United Kingdom. Through early regulatory engagement and harmonized documentation strategies, approvals were achieved significantly faster than typical regional benchmarks. This approach enabled rapid site activation and early patient enrollment.
An AI-supported feasibility assessment was used to identify oncology centers with strong experience in cervical cancer research and radiotherapy-integrated treatment protocols. This ensured that selected sites possessed both the clinical expertise and recruitment capabilities required for a complex early-phase oncology trial.
Successful trial delivery required coordinated execution across multiple geographies and clinical teams.ProRelix Research implemented a centralized governance structure supported by:
Localized recruitment strategies were also introduced to support patient enrollment. In India and Thailand, collaboration with women’s health advocacy groups and community healthcare organizations helped expand awareness of the study. Educational materials were translated into regional languages and distributed through local health networks. Technology-enabled monitoring further improved operational efficiency. Integrated electronic data capture systems and AI-assisted query management tools reduced manual workload and enhanced data accuracy.
The study delivered strong operational performance across all participating regions.
Enrollment Performance
→ Enrollment completed 2 months ahead of schedule
Patient Engagement
→ 94% patient retention rate
Operational Efficiency
→ 23% reduction in total trial execution costs
Data Quality
→ 98% data accuracy
→ 100% clean database lock
These outcomes highlight the impact of combining decentralized trial strategies, digital technologies, and strong global coordination.
This program highlights several important insights for modern oncology clinical trials:
By integrating advanced digital tools, regulatory expertise, and localized patient engagement strategies, ProRelix Research successfully supported the execution of a complex multinational oncology study. The program demonstrates how innovative clinical trial strategies can accelerate the development of promising therapies while expanding patient access to cutting-edge treatments.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.
